Sienna Biopharmaceuticals, Inc. announced on Mar. 12, 2018, that the first patient had been dosed in the company’s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin receptor kinase A, or TrkA, with minimal to no systemic exposure. The company expects to report top-line results, or TLRs, in the fourth quarter of 2018.